TTY Biopharm Co Ltd Total Assets
TTY Biopharm Co Ltd total assets. Based on the latest financial reports, TTY Biopharm Co Ltd (4105) holds total assets worth NT$11.68 Billion TWD (≈ $367.85 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TTY Biopharm Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of TTY Biopharm Co Ltd (2017–2025)
Total assets of TTY Biopharm Co Ltd from 2017 to 2025. This chart illustrates how TTY Biopharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest TTY Biopharm Co Ltd stock price today for real-time trading data and today's change.
TTY Biopharm Co Ltd - Asset Composition Analysis
TTY Biopharm Co Ltd Total Assets Breakdown (December 2025)
TTY Biopharm Co Ltd total assets breakdown as of December 2025. TTY Biopharm Co Ltd's total assets of NT$11.68 Billion consist of 53.0% current assets and 47.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.2% |
| Accounts Receivable | NT$1.50 Billion | 13.2% |
| Inventory | NT$1.39 Billion | 12.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how TTY Biopharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TTY Biopharm Co Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TTY Biopharm Co Ltd's current assets represent 53.0% of total assets in 2025, an increase from 52.6% in 2017.
- Cash Position: Cash and equivalents constituted 22.2% of total assets in 2025, up from 15.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
TTY Biopharm Co Ltd Competitors by Total Assets
Key competitors of TTY Biopharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
TTY Biopharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 1.63 | 1.99 |
| Quick Ratio | 1.32 | 1.29 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.57 Billion | NT$2.27 Billion | NT$2.46 Billion |
TTY Biopharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between TTY Biopharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | NT$11.35 Billion |
| Market Capitalization | $620.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values TTY Biopharm Co Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: TTY Biopharm Co Ltd's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for TTY Biopharm Co Ltd (2017–2025)
The table below shows the annual total assets of TTY Biopharm Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$11.35 Billion ≈ $357.53 Million |
+4.47% |
| 2024-12-31 | NT$10.86 Billion ≈ $342.24 Million |
+10.00% |
| 2023-12-31 | NT$9.87 Billion ≈ $311.11 Million |
+2.86% |
| 2022-12-31 | NT$9.60 Billion ≈ $302.47 Million |
+3.27% |
| 2021-12-31 | NT$9.30 Billion ≈ $292.89 Million |
-0.69% |
| 2020-12-31 | NT$9.36 Billion ≈ $294.92 Million |
-2.01% |
| 2019-12-31 | NT$9.55 Billion ≈ $300.96 Million |
+5.52% |
| 2018-12-31 | NT$9.05 Billion ≈ $285.22 Million |
-4.77% |
| 2017-12-31 | NT$9.51 Billion ≈ $299.52 Million |
-- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more